Abstracts tagged "T Cell"

Abstract Number: 0080 • ACR Convergence 2023
Pharmacological Inhibition of PRMT5 Demonstrates Broad Efficacy in Multiple Preclinical Models of Autoimmunity and Inflammation by Suppressing Th1, Th17 and TNF-Mediated Inflammatory Responses
Neha Bhagwat¹, Kumar Penmetsa², Matt Devalaraja³, Suzana Marusic⁴, Cornelia M. Weyand⁵, Shozo Ohtsuki⁶, Peggy Scherle¹ and Kris Vaddi¹, ¹Prelude Therapeutics, Inc, Wilmington, DE, ²Thermo Fisher Scientific, Philadelphia, PA, ³Nipuna Therapeutics, Waltham, MA, ⁴Hooke Laboratories LLC, Lawrence, MA, ⁵Mayo Clinic School of Medicine and Stanford University, Rochester, MN, ⁶Mayo Clinic College of Medicine and Science, Stanford University School of Medicine, Rochester, MN
Background/Purpose: Protein arginine methyltransferase 5 (PRMT5) is the major type II PRMT that catalyzes the formation of symmetrical dimethyl arginine (SDMA) on protein substrates and…
Abstract Number: 0303 • ACR Convergence 2023
Development of a Human Cytotoxic Myoinjury Model with CD8+ T Cells and Muscle Cells Differentiated from Human Induced Pluripotent Stem Cells
Hisanori Hasegawa¹, Soki Kashima², Makoto Otsu³, Hideki Taniguchi⁴ and Shinsuke Yasuda⁵, ¹Department of Rheumatology, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University (TMDU) and Institute of Global Affairs, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ²Laboratory of Immunology, Institute for Life and Medical Sciences, Kyoto University and Department of Urology, Akita University Graduate School of Medicine, Akita, Japan, ³Division of Hematology, Department of Laboratory Sciences, School of Allied Health Sciences, Kitasato University, Sagamihara, Japan, ⁴Division of Stem Cell Processing/Stem Cell Bank, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, Tokyo, Japan, ⁵Department of Rheumatology, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
Background/Purpose: CD8+ cytotoxic lymphocytes (CTLs) play a crucial role in the myoinjury of polymyositis (PM). Nonetheless, conventional treatment for PM depends on high-dose glucocorticoids with…
Abstract Number: 0937 • ACR Convergence 2023
IL-4+ and IFN-α+ Profibrotic T Cells Aggravate Systemic Sclerosis via STIM1/STING Signaling in SKG Mice
Ji Won Yang¹, Kun Hee Lee², Jin Seok Woo², Ha Yeon Jeong², JeongWon Choi², Eui-Jong Kwon¹, Mi-La Cho² and Sung-Hwan Park¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ²Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Systemic sclerosis (SS), also known as scleroderma, is a chronic autoimmune disease caused by inflammation, tissue fibrosis, and vasculopathy. Although the pathological mechanisms of…
Abstract Number: 1769 • ACR Convergence 2023
TNF-Stimulated Production of IL-15 by Fibroblast-Like Synoviocytes Mediates Human Resident Memory T Cells Development in Synovial Organoid Model
Margaret Chang¹, Maryrose Hahn², Madison Mangin¹, Brian Wauford¹, Rachel Blaustein³, Lauren Henderson¹, Kevin Wei⁴ and Peter Nigrovic¹, ¹Boston Children's Hospital, Boston, MA, ²Division of Immunology, Boston Children's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) are chronic autoimmune diseases that tend to flare repeatedly in the same joints, displaying joint-specific memory.…
Abstract Number: 0081 • ACR Convergence 2023
RA Disease Activity Influence the Frequency and Phenotype of Citrulline Reactive CD4 T Cells in DRB1*04:04 ACPA+ RA Patients
Cliff Rims¹, Anne Hocking¹, Sylvia Posso¹, Bernard Ng², Jeffrey Carlin³, Jane Buckner⁴ and Eddie James⁴, ¹Benaroya Research Institute, Seattle, WA, ²Veteran Affairs, Seattle, WA, ³Virginia Mason Medical Center, Seattle, WA, ⁴Benaroya Research Institute at Virginia Mason, Seattle, WA
Background/Purpose: The presence of ACPA in RA signifies an immune response toward citrullinated auto-antigens in disease pathogenesis and persistence. RA is a T cell mediated…
Abstract Number: 0431 • ACR Convergence 2023
Senescence and Cell Exhaustion in CD4+ and CD8+ Lymphocytes in Rheumatoid Arthritis Patients in Remission Without Treatment
Rodolfo Jiménez-Soto¹, Luis llorente², Guadalupe Lima¹, Luisa Alanis Saenz¹, Amairani Gomez Rodriguez¹, Hilda Marin Lopez¹, Erik Cimé-Aké¹ and Juan Jakez-Ocampo¹, ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Departamento de Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: T cells are important among the several risk factors and immunological markers implicated in rheumatoid arthritis (RA). The goal of this study was to…
Abstract Number: 1052 • ACR Convergence 2023
Unique Cellular and Autoantibody Signatures in Patients with irAEs Revealed by Longitudinal Immune Tracking
Sokratis Apostolidis¹, Kyra Sacksith¹, Bria Fulmer¹, Zoe Quandt², Mark Anderson², Terri Laufer³ and E. John Wherry¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of California San Francisco, San Franscisco, CA, ³University of Pennsylvania, Philadlephia, PA
Background/Purpose: The use of anti-PD-1 (aPD-1) immunotherapy has seen significant success in clinical practice, corresponding with a continued rise in clinical indications for multiple cancer…
Abstract Number: 1945 • ACR Convergence 2023
Case Series of 6 Patients Exhibiting Myositis as a Rheumatologic Adverse Events Related to Cancer Immunotherapy in Two Spanish Hospitals
Arturo Llobell¹, Inigo Gonzalez-Mazon², carmen secada³, Adrian Martin-Gutierrez³, Almudena García-Castaño³, Enrique Gallardo⁴, Soledad Retamozo⁵, Antonio Gomez-Centeno⁶, Luis Fernandez-Morales⁴, Jordi Gratacos Masmitja⁷ and Ricardo Blanco⁸, ¹Parc Tauli University Hospital, Barcelona, Spain, ²Hospital Universitario Marques de Valdecilla, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Parc Taulí University Hospital, Sabadell, Spain, ⁵Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX, Barcelona, Spain, ⁶Parc Taulí Hospital Universitari, Sabadell, Spain, ⁷University Hospital Parc Taulí, Sabadell, Spain, ⁸Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Myositis is a rare inflammatory complication associated with immune related adverse events (irAE) of immune checkpoints inhibition (ICI) immunotherapy1. It is characterized by musculoskeletal…
Abstract Number: 0082 • ACR Convergence 2023
A VAV1-Directed Molecular Glue Degrader, MRT-6160, Reduces Joint Inflammation in a Collagen-Induced Arthritis Autoimmune Disease Model
Adam Cartwright¹, Foram Desai², Sophia Nguyen², Alexandra Trouilloud², Elisa Liardo¹, Daric Wible², Ilaria Lamberto², Bradley Demarco², Chris King², Debora Bonenfant¹, Sharon Townson², Owen Wallace², Filip Janku², Laura McAllister¹, Alison Paterson² and Marisa Peluso², ¹Monte Rosa Therapeutics, Basel, Switzerland, ²Monte Rosa Therapeutics, Boston, MA
Background/Purpose: VAV1 is a member of the VAV family of guanine nucleotide exchange factors (GEFs) and plays a critical role in mediating T- and B-cell…
Abstract Number: 0455 • ACR Convergence 2023
Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody, Inhibits Peripheral T Cell Proliferation and Cytokine Secretion and Reduces Circulating PD-1 High Expressing CD4 and CD8 T Cells: Results from a Phase 1 Healthy Volunteer Clinical Trial
Kenneth Luu, Martin Dahl, Eric Hare, Cailin Sibley, Paul Lizzul and Bruce Randazzo, AnaptysBio, San Diego, CA
Background/Purpose: PD-1 pathway mutations increase human susceptibility to multiple autoimmune diseases, and insufficient PD-1 signaling can lead to dysregulated T cell responses. By targeting natural…
Abstract Number: 1159 • ACR Convergence 2023
Expanded Cytotoxic CD8+ T Cell Clones Characterize the Blood of Inclusion Body Myositis Patients
Miriam Fein¹, Laura Donlin¹, David Fernandez¹ and Lorien Shakib², ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY
Background/Purpose: Inclusion body myositis (IBM) is an inflammatory myopathy, characterized by CD8+ T cell infiltration of muscle and patients present with progressive muscle weakness and…
Abstract Number: 2136 • ACR Convergence 2023
Arthritogenic Cells Found in the Peripheral Blood of Rheumatoid Arthritis Patients Transfer the Disease to NSG-DR4 Mice
Janine Rupp¹, Johannes Fessler², Silvia Hayer³, Barbara Dreo⁴, Angelika Lackner², Patrizia Fasching², Wolfgang Helmberg², Peter Schlenke², Jens Thiel⁵, Guenter Steiner⁶, Cornelia M. Weyand⁷ and Martin Stradner², ¹Medical University Graz, Rochester, MN, ²Medical University of Graz, Graz, Austria, ³Medical University of VIenna, Vienna, Austria, ⁴Division of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ⁵University Hospital Freiburg, Freiburg, Germany, ⁶Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ⁷Mayo Clinic School of Medicine and Stanford University, Rochester, MN
Background/Purpose: T cells play an important role in the genesis of rheumatoid arthritis (RA). HLA class II genes, such as HLA-DRB1*0401 (HLA-DR4), confer the strongest…
Abstract Number: 0013 • ACR Convergence 2023
A Proliferating T Cell Signature in Blood Is Associated with Response to JAK Inhibitor Therapy in Rheumatoid Arthritis Patients
Mehreen Elahee¹, Kathryne Marks², Ifeoluwakiisi Adejoorin², Lin Chen², Derrick Todd², Jonathan Coblyn², Elena Massarotti², Susan Ritter², Michael Weinblatt³, Daniel Solomon⁴ and Deepak Rao², ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard Medical School, Waban, MA, ⁴Brigham and Women's Hospital, Newton, MA
Background/Purpose: There are multiple DMARDs available to treat rheumatoid arthritis (RA) yet there are no widely used predictive biomarkers to guide selection of a specific…
Abstract Number: 0083 • ACR Convergence 2023
Expression of mRNA Vaccine Antigen in Hematopoietic Cells Is Necessary for Induction of Optimal Vaccine-Specific CD4+ T Cell Responses
Julia Rood¹, Stephanie Suh Kyung Yoon², Mary O’Mara³, Mary Kate Heard³, Chaitali Bhadiadra³, Nhu Le³, Christabel Ameyaw Baah³, Norbert Pardi⁴ and Laurence Eisenlohr¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, PA, ³Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: mRNA vaccines are safe and remarkably effective, but rare cases of vaccine-induced autoimmunity have been reported, particularly in patients with underlying inflammatory disease. Mechanistic…
Abstract Number: 0602 • ACR Convergence 2023
Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN-101) Reveals Non-Redundant Roles of T Cell Co-Stimulation Pathways in Systemic Lupus Erythematosus
Elizabeth Repash, Tiffany Blair, Amanda Enstrom, Lawrence Evans, Susan Debrot, Katherine Lewis, Armand Bankhead, Stanford Peng and Stacey Dillon, Alpine Immune Sciences, Inc., Seattle, WA
Background/Purpose: CD28 and inducible T cell costimulator (ICOS) play nonredundant roles in T cell activation and inhibiting these pathways can ameliorate an (auto)immune response. Systemic…

« Previous Page
1
…
7
8
9
10
11
…
21
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].